文献速递神经免疫

年龄与多发性硬化全疾病谱对比增强病灶的关联

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
PubMed 文献 · Neurology · 2021-08-10

本研究基于4项大型随机对照试验数据集,分析年龄与多发性硬化不同病程中对比增强病灶(CELs)出现频率的关系。结果显示,各病程中CELs频率随年龄增长近乎线性下降,年龄是唯一与基线CELs风险相关的特征,且年龄越大风险越低。

要点

  • 各病程中CELs频率随年龄增长近乎线性下降。
  • 年龄是唯一与基线CELs风险相关的特征,年龄越大风险越低。
  • 治疗1年后CELs出现减少,但年龄相关下降趋势在多数试验中仍保留。

核心结论

  • 年龄与CELs出现的关联是多发性硬化全疾病谱的普遍现象。

研究设计与样本

  • 基于4项大型随机对照试验(RCT)原始数据:CombiRx(复发缓解型MS,n=1008)、ASCEND(继发进展型MS,n=889)、PROMISE(原发进展型MS,n=943)和INFORMS(原发进展型MS,n=970)。

主要发现

  • 基线时CELs频率因病程而异:CombiRx为39.6%,ASCEND为23.9%,PROMISE为14.0%,INFORMS为12.3%。
  • 各数据集CELs频率随年龄增长近乎线性下降,且该分布在各年龄组内基本保持。
  • 治疗1年后,所有试验CELs出现减少,ASCEND中几乎消失;年龄相关下降在CombiRx、PROMISE和INFORMS中仍保留。
  • 多变量逻辑回归显示,年龄是唯一与基线CELs风险相关的特征,年龄每增加1岁的比值比:CombiRx 0.96(95%CI 0.95-0.98),ASCEND 0.94(95%CI 0.92-0.97),PROMISE 0.94(95%CI 0.91-0.96),INFORMS 0.97(95%CI 0.94-0.99)。

临床怎么用

  • 在解读多发性硬化患者MRI对比增强病灶时,应考虑年龄因素,年龄越大出现CELs的可能性越低。

局限性

  • 研究基于随机对照试验数据集,结果需在真实世界多发性硬化数据集中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To investigate the association of age and the presence of contrast-enhancing lesions (CELs) on cranial MRI scans in different disease courses of multiple sclerosis (MS), we describe the frequency of CELs as a function of age in 4 large randomized controlled trial (RCT) datasets. METHODS: Using original trial data from CombiRx (Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis; clinicaltrials.gov identifier NCT00211887), a trial in relapsing-remitting MS; ASCEND (A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis; clinicaltrials.gov identifier NCT01416181), a trial in secondary progressive MS; and the 2 primary progressive MS trials PROMISE and INFORMS; clinicaltrials.gov identifier NCT00731692), we describe the occurrence of CELs per age group at baseline for the entire trial cohort and at 1 year follow-up in the treatment arms. RESULTS: CombiRx included 1,008, ASCEND 889, PROMISE 943, and INFORMS 970 participants. At baseline, CEL frequency differed between datasets according to disease course: 39.6% of CombiRx, 23.9% of ASCEND, 14.0% of PROMISE, and 12.3% of INFORMS participants had CELs. This distribution by disease course was largely preserved within each age group. In all datasets, there was an almost linear decrease of the percentage of participants with CELs with advancing age. After 1 year of experimental treatment, CEL occurrence was reduced in all trial datasets, and almost absent in ASCEND. The decrease of CEL occurrence with advancing age was preserved in CombiRx, PROMISE, and INFORMS after 1 year of treatment. We investigated the association of the baseline factors age, disease duration, sex, and EDSS with having CELs at baseline with multivariable binary logistic regression models. Age was the only characteristic associated with the risk of CELs at baseline in all datasets, with higher age associated with a lower risk of CELs (odds ratios for having CELs at baseline per year increase in age: CombiRx: 0.96, 95% confidence interval [CI] 0.95-0.98; ASCEND: 0.94, 95% CI 0.92-0.97; PROMISE: 0.94, 95% CI 0.91-0.96; INFORMS: 0.97, 95% CI 0.94-0.99). DISCUSSION: Our analysis of 4 large, well-characterized RCT datasets shows that the association of age and CEL occurrence is a general phenomenon across the spectrum of MS disease courses. Our findings should be replicated in real-world MS datasets.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Koch MW, Mostert J, Zhang Y, et al. Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. Neurology. 2021. PMID: 34376508. doi:10.1212/WNL.0000000000012603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。